Ex vivo activity of the ACT new components pyronaridine and piperaquine in comparison with conventional ACT drugs against isolates of Plasmodium falciparum

BACKGROUND: The aim of the present work was to assess i) ex vivo activity of pyronaridine (PND) and piperaquine (PPQ), as new components of artemisinin-based combination therapy (ACT), to define susceptibility baseline, ii) their activities compared to other partner drugs, namely monodesethylamodiaq...

Descripción completa

Detalles Bibliográficos
Autores principales: Pascual, Aurélie, Parola, Philippe, Benoit-Vical, Françoise, Simon, Fabrice, Malvy, Denis, Picot, Stéphane, Delaunay, Pascal, Basset, Didier, Maubon, Danièle, Faugère, Bernard, Ménard, Guillaume, Bourgeois, Nathalie, Oeuvray, Claude, Didillon, Eric, Rogier, Christophe, Pradines, Bruno
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3305508/
https://www.ncbi.nlm.nih.gov/pubmed/22333675
http://dx.doi.org/10.1186/1475-2875-11-45

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3305508/
https://www.ncbi.nlm.nih.gov/pubmed/22333675
http://dx.doi.org/10.1186/1475-2875-11-45

Ejemplares similares